TY - JOUR
T1 - Cancer biomarkers
T2 - Emerging trends and clinical implications for personalized treatment
AU - Passaro, Antonio
AU - Al Bakir, Maise
AU - Hamilton, Emily G.
AU - Diehn, Maximilian
AU - André, Fabrice
AU - Roy-Chowdhuri, Sinchita
AU - Mountzios, Giannis
AU - Wistuba, Ignacio I.
AU - Swanton, Charles
AU - Peters, Solange
N1 - Publisher Copyright:
© 2024 Elsevier Inc.
PY - 2024/3/28
Y1 - 2024/3/28
N2 - The integration of cancer biomarkers into oncology has revolutionized cancer treatment, yielding remarkable advancements in cancer therapeutics and the prognosis of cancer patients. The development of personalized medicine represents a turning point and a new paradigm in cancer management, as biomarkers enable oncologists to tailor treatments based on the unique molecular profile of each patient's tumor. In this review, we discuss the scientific milestones of cancer biomarkers and explore future possibilities to improve the management of patients with solid tumors. This progress is primarily attributed to the biological characterization of cancers, advancements in testing methodologies, elucidation of the immune microenvironment, and the ability to profile circulating tumor fractions. Integrating these insights promises to continually advance the precision oncology field, fostering better patient outcomes.
AB - The integration of cancer biomarkers into oncology has revolutionized cancer treatment, yielding remarkable advancements in cancer therapeutics and the prognosis of cancer patients. The development of personalized medicine represents a turning point and a new paradigm in cancer management, as biomarkers enable oncologists to tailor treatments based on the unique molecular profile of each patient's tumor. In this review, we discuss the scientific milestones of cancer biomarkers and explore future possibilities to improve the management of patients with solid tumors. This progress is primarily attributed to the biological characterization of cancers, advancements in testing methodologies, elucidation of the immune microenvironment, and the ability to profile circulating tumor fractions. Integrating these insights promises to continually advance the precision oncology field, fostering better patient outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85188420233&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85188420233&partnerID=8YFLogxK
U2 - 10.1016/j.cell.2024.02.041
DO - 10.1016/j.cell.2024.02.041
M3 - Review article
C2 - 38552610
AN - SCOPUS:85188420233
SN - 0092-8674
VL - 187
SP - 1617
EP - 1635
JO - Cell
JF - Cell
IS - 7
ER -